Skip to content

Effect of Transcranial Neuromodulation (TN) associated with a program based on meditation on the pain of women with Migraine

Effect of Transcranial Magnetic Stimulation (TMS) associated with a program based on Mindfulness meditation on the pain of women with Migraine: a feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2md8855
Enrollment
Unknown
Registered
2024-06-06
Start date
2024-06-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disorders. Migraine without Aura. Migraine with Aura

Interventions

This is a non-blind, single-group feasibility study with 12 women diagnosed with migraine. 8 Transcranial Magnetic Stimulation (TMS) sessions will be carried out in the left dorsolateral prefrontal co
E02.621.820
F02.463.551

Sponsors

Centro de Ciências da Saúde da Universidade Federal do Espírito Santo
Lead Sponsor
Centro de Ciências da Saúde da Universidade Federal do Espírito Santo
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women (cis or trans). Aged between 18 and 65 years old. Present a diagnosis of Migraine according to the criteria of The International Classification of Headache Disorders (ICHD-3) 2018, for more than 3 months: at least five attacks meeting criteria from B to D; headache attacks lasting 4-72 hours (without treatment or with ineffective treatment); the headache has at least two of the following characteristics: unilateral location, pulsatile character, moderate or severe pain intensity, exacerbated by or causing the individual to avoid routine physical activities (for example: walking or climbing stairs); during headache, at least one of the following: nausea and/or vomiting, and photophobia and phonophobia, not better explained by another ICHD-3 diagnosis

Exclusion criteria

Exclusion criteria: Participants who are at a peak of cardiovascular disease or have severe cardiopulmonary disease. With sequelae of neurological diseases. Use walking aids. With visual and hearing impairments. With amputations of lower and upper limbs. With rheumatic diseases in the acute phase. Cancer. Epilepsy. Fractures of the skull, neck or rib cage. Severe osteoporosis. People with a pacemaker or implantable cardioverter defibrillator, epilepsy or who underwent surgery less than 1 year ago. Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frame
The feasibility of the study for the future development of a clinical trial.

Secondary

MeasureTime frame
The recruitment rate, patient adherence rate to the treatment protocol, the acceptability of the intervention by the participants and the safety of the intervention protocol.

Countries

Brazil

Contacts

Public ContactSynthia Marcolano

Universidade Federal do Espírito Santo

departamento.deis@ufes.br+55-27-33357201

Outcome results

None listed

Source: REBEC (via WHO ICTRP)